Epilepsy

Take a look at some of the most-anticipated clinical trials with expected data readouts in the second half of 2024 that researchers and clinicians in neurology should keep an eye out on.

Brivaracetam was largely well tolerated and shown to be effective for a proportion of patients with intellectual disability, indicated by similar responses across different levels of intellectual disability severity.

Here's some of what is coming soon to NeurologyLive® this week.

The pediatric epileptologist at Children's Hospital Colorado talked about a comprehensive review of various studies assessing fenfluramine in severe seizures associated with developmental and epileptic encephalopathies. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on multiple system atrophy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 12, 2024.

Catch up on any of the neurology news headlines you may have missed over the course of June 2024, compiled all into one place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on headache and nerve decompression surgery.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 5, 2024.

Here's some of what is coming soon to NeurologyLive® this week.

The professor and chair of neurology at New York Medical College discussed her extensive involvement in neurology education and the recent efforts to enhance neurology education through various programs. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on epilepsy/Dravet syndrome.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 28, 2024.

As part of our monthly clinician spotlight, NeurologyLive® highlighted seizure disorder expert Danielle Andrade, MD, MSc, FRCPC, director of the Adult Genetic Epilepsy Program at the University of Toronto.

Clinically meaningful reductions in seizures through fenfluramine is likely to contribute to nonseizure benefits such as improvement in comorbidities, decreased use of other antiseizure medications, and reduction in premature death.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network. for the week ending June 22, 2024. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Alzheimer disease/dementia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 21, 2024.

The phase 3 trials investigating soticlestat for Dravet syndrome and Lennox-Gastaut syndrome (LGS) yielded mixed results on primary end points but showed promise in secondary outcomes.

A recent study showed a significant association between sleep apnea, additional sleep characteristics, and late-onset epilepsy in older adults, even after adjusting for comorbidities.

Marinus Pharmaceuticals reported that it will continue to analyze the full dataset and engage with the FDA to discuss the future of ganaxolone for treating refractory status epilepticus.

Initial data from a few pediatric and adult patients with Rett syndrome showed that treatment with TSHA-102 resulted in numerous positive enhancements across multiple efficacy measures and clinical domains.

Here's some of what is coming soon to NeurologyLive® this week.